Both nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) are pleiotropic inflammatory mediators that are overproduced during and involved in the pathogenesis of chronic inflammations and infections. [1] [2] [3] [4] [5] [6] [7] NO is synthesized from L-arginine by nitric oxide synthase (NOS). To date, three isoforms of NOS have been identified: endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). While nNOS and eNOS are constitutively expressed, iNOS is expressed in response to proinflammatory stimuli such as the bacterial endotoxin lipopolysaccharide (LPS), tumor necrosis factor (TNF)-a and interferon (IFN)-g. 2) Although iNOS has been shown to play a critical role in host survival against infection with Mycobacterium tuberculosis, 1) overproduction of NO by iNOS has been implicated in the pathogenesis of many disease states. [1] [2] [3] For example, Type I diabetes is the result of loss of insulin production due to selective destruction of b cells in the pancreatic islets of Langerhans. NO has been proposed to play an active role in this destructive process in addition to the Fas-Fas ligand mediated destruction pathway. 8) IFN-g produced by diabetogenic Th1 cells also stimulates infiltrating macrophage activation and NO production. 8) PGE 2 is a major metabolite of the cyclooxygenase (COX) enzyme. COX exists in at least two different isoforms, COX-1 and COX-2. While COX-1 is constitutively expressed in most tissues and is thought to be responsible for regulating normal physiological functions, 4) COX-2 is induced in macrophages, fibroblasts and several other cell types by proinflammatory stimuli, similar to iNOS. 4) Furthermore, COX-2 is responsible for the production of large amounts of proinflammatory PGs at inflammatory sites. 4) For instance, periodontitis is a polymicrobial infection characterized by a destructive inflammatory process affecting tooth supporting tissues that results in alveolar bone resorption and bone loss. Experimental evidence suggests that Porphyromonas gingivalis, a Gram-negative anaerobic bacterium, is the major etiological agent of chronic periodontitis. 9) It has recently been shown that the production of PGE 2 is responsible for the LPS-induced alveolar bone loss. 10) In addition, significantly increased numbers of iNOS-positive cells have been observed in samples from gingivitis and periodontitis patients. 11) Treatment with a selective iNOS inhibitor was found to be effective against ligature-induced periodontitis in rats. 12) Therefore, as chronic phases of inflammation and infection strongly correlate with increased production of both NO and PGE 2 , substances that inhibit both NO and PGE 2 production could be of therapeutic benefit.
Anti-inflammatory effects of several kinds of mushrooms have been previously reported. [13] [14] [15] Based on these earlier studies, we screened extracts from 16 varieties of edible and commercially grown mushroom for their ability to inhibit NO production by mouse peritoneal macrophages stimulated with LPS and IFN-g (LPS/IFN-g). We found that the ethylacetate (AcOEt) extract of the brown mushroom Agaricus bisporus IMBACH inhibited NO production without obvious toxicity to the macrophages. Following activity-directed fractionation and spectroscopic characterization (   1   H-and   13 C-NMR, and MS), we identified 2-amino-3H-phenoxazine-3-one (APO) (Fig. 1) as the substance responsible for inhibit- Accumulating evidence suggests that nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) are involved in the pathogenesis of various chronic inflammatory diseases and cancer. During the course of a screening program to identify natural anti-inflammatory substances, we isolated the compound 2-amino-3H-phenoxazin-3-one (APO) from an extract of the edible brown mushroom Agaricus bisporus IMBACH. APO inhibited NO production by mouse peritoneal macrophages in response to the pro-inflammatory stimuli lipopolysaccharide (LPS) and interferon (IFN)-g g (LPS/IFN-g g) at low concentrations (IC 50 ‫5.1؍‬ m mM) through reduced inducible NO synthase protein expression. PGE 2 production by LPS/IFN-g g-stimulated macrophages was inhibited by APO at much lower concentrations (IC 50 ‫72.0؍‬ m mM) than those required for the inhibition of NO production. Mechanistic analysis showed that APO inhibited both cyclooxygenase (COX)-1 and COX-2 enzyme activities with almost equal selectivity. Secretion of NO and the pro-inflammatory cytokine IL-6 by IFN-g g-activated RAW264.7 cells, a murine macrophage-like cell line, was also dose-dependently reduced by APO. Furthermore, APO increased the secretion of the anti-inflammatory cytokine IL-4 by antigen-stimulated T cells and promoted the polarization of CD4 ing NO production by LPS/IFN-g-stimulated macrophages. APO has been previously isolated as an antibacterial substance from actinomycetes. 16) As APO has essentially the same structure as actinomycin D, which exhibits a strong anticancer effect, the potential cytotoxic and/or anti-proliferative effects of APO on several malignant cell lines have been studied in vitro and in vivo. [17] [18] [19] APO has also been shown to inhibit the growth of Chlamydia pneumoniae in human monocytic THP-1 cells. 20) However, to our knowledge, antiinflammatory functions for APO have not yet been reported. In the present study, we investigated the anti-inflammatory and immunomodulatory activities of APO in vitro.
MATERIALS AND METHODS
Mice BALB/c female mice, aged 8-12 weeks, were purchased from Charles River Japan (Kanagawa, Japan). All animal experiments described in this article were conducted according to the guidelines of the Animal Experiments Review Board at our Institute.
Reagents Brown mushrooms cultivated in Hyogo Pref. were purchased at supermarkets in Okayama. Lipopolysaccharide (LPS) (Escherichia coli 055:B5) was obtained from Difco Laboratories (Detroit, MI, U.S.A.). Murine recombinant interferon-g (IFN-g) and sugi basic protein (SBP), a major allergen of Japanese cedar (Cryptomeria japonica) pollen, were prepared and purified in our laboratories. NS-398, indomethacin and aspirin were purchased from Wako Pure Chemical Industries (Osaka, Japan). Cytokine standards for ELISA (IL-4, IL-6, IL-10, and IL-12) were obtained from BD PharMingen (San Diego, CA, U.S.A.). The following monoclonal antibody (mAb) pairs for ELISA capture and biotinylated detection were purchased from BD PharMingen: for TNF-a, G281-2626 and MP6-XT3; for IL-6, MP5-20F3 and MP5-32C11; for IL-10, JES5-2A5 and SXC-1; and for IL-12 p70, 9A5 and C17.8.
Isolation of APO from Extracts of Brown Mushroom Brown mushrooms were dried in an oven and pulverized with a mixer. The pulverized material was extracted with 20 ml ethylacetate (AcOEt) per 1 g of material for 2 h at room temperature. APO was purified to Ͼ95% purity from the extract using an HPLC C30 column (Develosil RPAQUEOUS-AR-5, Nomura Chemical, Aichi Pref., Japan) equilibrated with distilled water containing 0.1% TFA. Elution was performed with a linear gradient of 0 to 90% acetonitrile. Approximately 1 mg of APO per 1 g of dried brown mushroom was obtained. APO Cell Cultures and Stimulation Murine peritoneal macrophages were elicited by intraperitoneal (i.p.) injection of 2 ml 4% Brewer's thioglycollate medium (Nissui Pharmaceutical, Tokyo, Japan) into the peritoneal cavities of BALB/c mice. Peritoneal exudate cells were collected by lavage 3 to 4 d after injection. Cells were washed twice and plated into 10-cm diameter plastic dishes (Nippon Becton Dickinson, Tokyo, Japan) at a density of 1ϫ10 8 cells/dish in 10 ml of RPMI1640 medium (Nissui Pharmaceutical) containing 10% (v/v) FBS (Life Technologies, Grand Island, NY, U.S.A.). After 2 h incubation at 37°C in a humidified atmosphere of 5% CO 2 and 95% air, non-adherent cells were remov-ed by rinsing. RPMI1640 medium containing 10% FBS was then added to the adherent cells, and cells recovered with a cell scraper (Nippon Becton Dickinson) and used as macrophages. The murine macrophage-like cell line, RAW264.7, was maintained in RPMI1640 medium containing 10% FBS.
For pro-inflammatory cytokine production, peritoneal macrophages or RAW264.7 cells were seeded at 5ϫ10 4 cells per well in flat bottom 96-well microtiter plates and stimulated with LPS (2 mg/ml) and IFN-g (10 IU/ml) in the presence or absence of various concentrations of APO for 24 to 72 h. After the incubation period, the culture supernatants were collected for the measurement of NO, PGE 2 , and cytokines.
To examine the effect of APO on cytokine production by antigen-stimulated T cells, BALB/c mice were immunized three times by subcutaneous (s.c.) and i.p. injection with 10 mg SBP adsorbed onto 2 mg alum adjuvant every 2 weeks. Cervical, submandibular, inguinal, and mesenteric lymph nodes were obtained 7 d after the last immunization. Lymph node cells (1.2ϫ10 6 /ml) were stimulated in 96-well plates with 10 mg/ml SBP and syngeneic spleen cells (3ϫ10 6 /ml) pretreated with mitomycin C (MMC) (50 mg/ml) as antigen presenting cells (APC) for 30 min at 37°C in the presence or absence of various concentrations of APO. After 3 and 6 d, culture supernatants were collected and stored at Ϫ80°C until cytokine analysis.
To assess the effects of APO on CD4 ϩ helper T cell differentiation, CD4
ϩ T cells were purified from spleen cells of SBP-immunized BALB/c mice as described previously. 22) Briefly, spleen cells were incubated in FCS-coated plastic plates for 1.5 h at 37°C. After incubation, non-adherent cells were seeded onto goat anti-mouse Ig (DAKO, Glostrup, Denmark)-coated plates for 1 h at 4°C to remove B cells, and the recovered non-adherent cells incubated with ascites fluid containing rat anti-mouse CD4 mAb from the GK1.5 hybridoma (a gift from Dr. E. Nakayama, Okayama University Medical School, Okayama, Japan) for 30 min on ice, and then washed twice with medium. The harvested cells were incubated on goat anti-rat IgG (ICN Pharmaceuticals, Aurora, OH)-coated plates for 1 h at 4°C to recover the CD4 ϩ T cells. Adherent cells consisted of CD4 ϩ T cells with a purity of more than 90% as verified by flow cytometric analysis.
Purified CD4 ϩ T cells (2ϫ10 6 /ml) were stimulated in 24-well plates with 10 mg/ml SBP and MMC-treated BALB/c mouse spleen cells (4.8ϫ10 6 /ml) in the presence or absence of various APO concentrations (Primary culture). On days 3 and 7, culture supernatants were collected for cytokine assays. After 7 d, T cells were harvested, washed, and re-stimulated at 4ϫ10 5 cells/ml with 10 mg/ml SBP and MMCtreated BALB/c mouse spleen cells (Secondary culture). After 48 h incubation, culture supernatants were collected for cytokine assays.
Levels of NO in the culture supernatants were estimated by the accumulation of the stable NO metabolite nitrite anion using the Griess assay. Levels of IL-6, IL-10, IL-12 and PGE 2 were measured by ELISA. PGE 2 was measured using an ELISA kit (Amersham Pharmacia Biotech, Tokyo, Japan). The lower limits of detection were 25, 250, 16 and 50 pg/ml for IL-6, IL-10, IL-12 and PGE 2 , respectively.
For measurement of cell proliferation, 20 ml alamarBlue dye (Trek Diagnostic Systems, OH), a redox indicator, was added to each microplate well for the last 2 to 3 h of the incubation period. 23) Fluorescence intensity (FI) was measured at 544 nm excitation wavelength and 590 nm emission wavelength.
Western Immunoblot Analysis of iNOS Cellular proteins were isolated from stimulated macrophages at 2ϫ10 7 cells/ml on ice for 30 min in lysis buffer containing 0.5% NP-40, 0.15 M NaCl, 2 mM EDTA (4Na), 50 mM Tris, 10 mM iodoacetamide and 1 mM phenylmethylsulfonylfluoride. Nuclei and cell debris were removed by centrifugation at 500ϫg for 10 min. Cell lysates (30 mg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Multigel 2/15; Daiichi Pure Chemicals, Tokyo, Japan) under reducing conditions, and transferred to nitrocellulose membranes (Micron Separations, Westborough, MA, U.S.A.) by semi-dry electrophoretic transfer. Nitrocellulose membranes were then blocked with a solution containing 10% Block Ace (Dainippon Pharmaceutical, Osaka, Japan) for 1 h, and incubated with anti-mouse iNOS antibody (Ab) (1/500 dilution) (Wako Pure Chemical Industries) as primary Ab for 1 h. After removing the primary Ab, membranes were washed three times with Tris-buffered saline (TBS) containing 0.05% Tween 20, and then incubated with a 1 : 1000 dilution of secondary Ab conjugated to horseradish peroxidase (Dako) for 1 h. The membranes were then washed three times and reaction products visualized using the enhanced chemiluminescence (ECL) Western blot system (Amersham).
Measurement of Cyclooxygenase Activity COX-1 and COX-2 enzyme activities were examined using a cyclooxygenase inhibitor screening assay kit (Cayman Chemical). Briefly, ovine COX-1 or COX-2 was pre-incubated at 37°C for 2 min with or without various concentrations of APO in 0.1 M Tris-HCl (pH 8.0) containing 5 mM EDTA, 2 mM phenol and 1 mM heme. Reactions were initiated by the addition of arachidonic acid to a final concentration of 100 mM, and reaction mixtures then incubated at 37°C for a further 2 min. One twentieth volume of 1 M HCl was added to the reaction mixtures to stop enzyme catalysis, followed by one tenth volume of saturated stannous chloride (50 mg/ml). Reaction mixtures were incubated for 5 min at room temperature, after which the amounts of PGE 2 formed during the reaction were measured by enzyme immunoassay. Statistical Analysis Results were analyzed by Student's unpaired t test. p-values less than 0.05 were considered statistically significant.
RESULTS

APO Inhibits the Production of both NO and PGE 2 by
Macrophages in Response to Inflammatory Stimuli During our screening program designed to identify substances that inhibit NO production by LPS/IFN-g-stimulated peritoneal macrophages, we isolated APO from an AcOEt extract of brown mushroom. Figure 2A shows the dose-response curve of the inhibitory effect of APO on NO production. APO effectively inhibited NO production at relatively low concentrations (IC 50 ϭ1.5Ϯ0.4 mM, meanϮS.D., nϭ4). We also observed that APO inhibited PGE 2 production efficiently at much lower concentrations than those required to inhibit NO production (IC 50 ϭ0.27Ϯ0.09 mM, meanϮS.D., nϭ3) (Fig. 2B) . The decreased production of both NO and PGE 2 in the presence of APO was not due to toxic effects on macrophages, as the growth of LPS/IFN-g-stimulated macrophages was not inhibited by APO, but rather growth was augmented over the range of 0.6-2.5 mM APO (Fig.  2C) .
The inhibitory effect of APO on both NO and PGE 2 was compared with two non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin and aspirin (Fig. 3) . For inhibition of PGE 2 , APO was less effective than indomethacin, but 4 times superior to aspirin. However, both indomethacin and aspirin exhibited only minimal inhibitory effects on NO production.
In Th1 cell-mediated chronic inflammatory disease, IFN-g produced by activated Th1 cells induces macrophages to produce pro-inflammatory cytokines and effector molecules, such as IL-1, IL-6, and NO.
24) Therefore, we examined whether APO could inhibit NO and IL-6 production by the murine macrophage cell line RAW264.7 stimulated with IFN-g. IFN-g-stimulated RAW264.7 cells were used, as the levels of NO and IL-6 produced by these cells were substantially higher than those produced by peritoneal macrophages in response to the same concentrations of IFN-g (data not shown). As shown in Fig. 4 , APO effectively and dosedependently inhibited both NO and IL-6 production by RAW264.7 cells. At 6 mM of APO, NO and IL-6 production was inhibited by 56% and 51% of the medium-only control, respectively. The decreased NO and IL-6 production was not due to the inhibition of RAW264.7 cell growth (data not shown). These results suggested that APO inhibited the production of pro-inflammatory signals by macrophages in response to the type 1 cytokine IFN-g and bacterial toxin LPS.
Analysis of the Mechanism of Action of APO on the Inhibition of NO and PGE 2 Production APO did not inhibit NO production by macrophages when APO was added to the culture 18 h after LPS/IFN-g stimulation (data not shown). This suggested that the reduction of NO accumulation by APO was not a result of direct inhibition of the iNOS enzyme. We then examined whether APO affected iNOS protein expression levels. Stimulation of peritoneal macrophages with LPS/IFN-g resulted in accumulation of the 130 kDa iNOS protein as determined by Western blot analysis (Fig.  5A) . APO reduced iNOS protein levels in a dose-dependent manner. Densitometric scanning of immunoblots showed that the addition of 0.74 and 2.9 mM APO reduced iNOS protein levels by 26% and 75%, respectively, compared to LPS/IFNg-stimulated cells without APO. As iNOS protein expression levels correlated well with the reduced accumulation of NO (Fig. 5B) , our results suggested that APO inhibited NO synthesis through the reduction of iNOS expression.
We next investigated whether the inhibitory effect of APO on PGE 2 production was mediated via inhibition of COX enzyme activity. To this end, we examined the inhibitory effect of APO on purified ovine COX enzymes. As shown in Fig. 6 , APO inhibited the enzyme activity of both COX-1 and COX-2, similar to indomethacin. In contrast, the highly selective COX-2 inhibitor, NS-398, only inhibited COX-2 activity without affecting COX-1 activity. The ratio of COX-1 IC 50 to COX-2 IC 50 was 1.33 for APO, which suggested that APO had nearly equal selectivity for the two COX isoforms.
APO Promoted Th2 Differentiation through DownRegulation of IL-12 Production
To examine the effect of APO on cytokine production by antigen-stimulated T cells, lymph node cells from SBP-immunized BALB/c mice were stimulated with SBP and MMC-treated spleen cells from normal BALB/c mice as APC in the presence or absence of various concentrations of APO. While preliminary results showed that the addition of APO to the cultures resulted in a dose-dependent decrease in IFN-g production, IL-4 levels were reciprocally up-regulated (data not shown). At 5 mM APO, IL-4 levels increased 5.2-fold compared with the control culture. This suggested that APO may promote Th2 differentiation. To further examine this possibility, CD4 ϩ T cells were purified from spleen cells taken from SBP/Alumimmunized BALB/c mice, and stimulated with SBP and APC in the presence or absence of various concentrations of APO for 7 d at 37°C (Primary culture). After the incubation period, T cells were recovered, washed, and re-stimulated with SBP and APC (Secondary culture). Figure 7 shows the profiles of IFN-g and IL-4 production for both primary and secondary cultures. In primary cultures, IFN-g production on days 3 and 7 was decreased by the addition of APO, while IL-4 production was increased by high APO concentrations after a 7-d incubation period (Figs. 7A, B) . For the secondary cultures, the amounts of IFN-g produced were comparable across the different APO concentrations (Fig. 7C) . However, IL-4 levels were dose-dependently increased by the addition of APO to the primary culture (Fig. 7D) . The ratio of IL-4 to IFN-g was dose-dependently augmented by APO (data not shown) up to a 4.6-fold increase at 2.4 mM APO. APO also dose-dependently increased the production of another Th2 cytokine, IL-5 (data not shown). As it is well known that IL-4 is a prerequisite for Th2 development, these results suggested that APO promoted Th2 differentiation through the up-regulation of IL-4 production.
IL-12, which induces IFN-g production by T and NK cells, is a critical factor for Th1 cell development. 25) As abrogation of IL-12 production by macrophages and dendritic cells polarizes the immune response toward a Th2 cytokine profile, [26] [27] [28] we examined whether APO inhibited IL-12 production by LPS/IFN-g-stimulated macrophages. As shown in Fig. 8 , stimulation of peritoneal macrophages with LPS/IFNg resulted in the secretion of substantial amounts of IL-12. Addition of APO led to a partial but significant reduction of IL-12 production. In contrast, no reduction in IL-12 production was observed after the addition of aspirin at the same concentrations that inhibited PGE 2 production (Figs. 3, 8) . We then tested for IL-10 levels in the culture supernatants since a reciprocal relationship between IL-10 and IL-12 production has been reported previously. 29) However, levels of IL-10 produced by LPS/IFN-g-stimulated macrophages in the presence of APO were comparable with those observed in control cultures (data not shown). involved in tissue damage through peroxynitrite formation with reactive oxygen species that are also generated by macrophages at sites of bacterial infection. 2) In the present study, we have shown that APO isolated from an AcOEt extract of the edible brown mushroom Agaricus bisporus IMBACH inhibits NO production by LPS/IFN-g-stimulated macrophages through the reduction of iNOS protein expression. APO also inhibited the production of NO by peritoneal macrophages stimulated with LPS only, although the levels of NO were much lower than those produced in response to LPS/IFN-g (data not shown). The inhibition of NO production did not appear to be due to cytotoxic effects on the macrophages, since peritoneal macrophage growth was not inhibited, but rather augmented by the addition of APO. NO production by IFN-g-stimulated macrophages was also dosedependently inhibited by APO. Calder et al. reported that autocrine TNF-a signaling through the TNF p55 receptor is involved in IFN-g-induced NO production by macrophages. 30) This IFN-g-stimulated macrophage activation and resultant NO production have been implicated in the pathogenesis of Th1 cell-mediated organ-specific autoimmune disease models and inflammatory bowel disease (IBD). Th1 cell-derived IFN-g stimulates regional macrophage or colonic epithelial cell activation and NO activation, which then leads to tissue destruction. [30] [31] [32] APO-induced inhibition of NO production was not restricted to macrophages stimulated by bacterial toxin LPS and/or IFN-g. TNF-a stimulates osteoblasts to secrete bone resorbing cytokines (IL-1b and IL-6) and NO that act directly on osteoclasts to cause bone resorption. 33) We examined the effect of APO on NO production by the murine osteoblast-like cell line MC3T3-E1 in response to TNF-a and IL-1b. APO dose-dependently reduced NO production by TNF-a-or IL-1b-stimulated MC3T3-E1 cells (data not shown). In addition, IL-6 production by macrophages and MC3T3-E1 cells in response to pro-inflammatory cytokines was also inhibited by APO (Fig. 3 and data not shown) . IL-6, as a pro-inflammatory cytokine, has been demonstrated to be involved in the pathogenesis of rheumatoid arthritis and IBD. 34) These results suggested that APO can down-regulate the inflammatory cascade that can lead to tissue and bone destruction at sites of inflammation.
Intracellular signaling pathways of APO leading to the inhibition of iNOS expression and proinflammatory cytokine production remain to be clarified. It is well known that nuclear transcription factor kB (NF-kB) plays an essential role in the expression of genes involved in immune and inflammatory responses. LPS and proinflammatory cytokines TNFa and IL-1 induce the activation of NF-kB resulting in the transcription of multiple inflammatory mediators including iNOS, COX-2, IL-6 and IL-12.
35-37) NF-kB and enzymes involved in its activation can therefore be a target for anti-inflammatory treatment. In fact, a great number of natural substances have been shown to exhibit anti-inflammatory functions by suppressing NF-kB activation.
38) Therefore, it is worth examining whether APO inhibits LPS-induced iNOS expression and proinflammatory cytokine production via inhibiting NF-kB signaling pathway. Studies are underway to address this possibility.
APO also inhibited PGE 2 production by LPS/IFN-g-stimulated macrophages at much lower concentrations than those required for the inhibition of NO production. Mechanistic analysis showed that APO inhibited both COX-1 and COX-2 enzyme activity with almost equal selectivity. Interestingly, APO shares this functional feature with NSAIDs such as indomethacin and aspirin. On a per molar basis, the PGE 2 -inhibitory potency of APO was superior to aspirin, but inferior to that of indomethacin.
Inhibitors of iNOS and COX-2 have been considered as potential therapeutic agents for preventing inflammatory disease. [39] [40] [41] [42] [43] Sakaguchi et al. reported that oral administration of the selective iNOS inhibitor 1400W into type II collageninduced arthritis (CIA) mice had no effect on arthritic inflammation or bone destruction. However, the combined administration of 1400W and a COX inhibitor (indomethacin) showed a synergistic ameliorative effect. 39) These results suggest that APO may also be of therapeutic benefit in inflammatory disorders.
Another interesting point to note is that APO augmented IL-4 production by antigen-stimulated T cells and promoted the polarization of CD4 ϩ Th cells toward the IL-4-producing Th2 phenotype at equimolar concentrations that inhibited NO production. It seems unlikely that the APO-induced augmentation of IL-4 secretion was due to the inhibition of either PGE 2 or NO production, as it has been shown that both PGE 2 and NO promote rather than suppress Th2 responses. 44, 45) We focused on the potential role of IL-12 during Th cell development, as methods that abrogate IL-12 production by macrophages or dendritic cells render them able to promote Th2 cell polarization. [26] [27] [28] For instance, dendritic cells, in which IL-12 p35 gene expression was silenced via specific small interfering RNA, polarized the immune response toward a Th2 cytokine profile. 26) In our study, APO partially but significantly abrogated IL-12 production by peritoneal macrophages stimulated with LPS/IFN-g in the range of concentrations that promoted Th2 cell polarization. Although aspirin has been shown to inhibit secretion of IL-12 at 1 to 5 mM, 37) no significant reduction in IL-12 secretion was observed in the range of 0.2 to 10 mM in our study. As aspirin at 10 mM completely inhibited PGE 2 production by LPS/IFN-g-stimulated macrophages (Fig. 3) , our results suggested that APO promoted Th2 differentiation, at least in part through the down-regulation of IL-12 production, but not via inhibition of PGE 2 production.
We isolated APO from the AcOEt extract of the brown mushroom. However, it is unclear how APO is synthesized as a natural product in the brown mushroom. Phytochemically, APO was identified as the transformation product of 2-benzoxazolinone (BOA) by soil-and root-colonizing bacteria. 46, 47) Recently, APO has been shown to be biotransformed from BOA and 2-hydroxy-1,4-benzoxazin-3-one (HBOA) by endophytic fungi isolated from Aphelandra tetragona. 48) This biotransformation proceeds via o-aminophenol as a key intermediate. Both BOA and HBOA are compounds called phytoanticipins and present in healthy plants as substances to overcome microbial diseases and herbivory. In addition to the results of our study, Kim et al. 49) and Aulinger et al. 50) reported the isolation of APO from the edible mushroom Lepiota americana PK., and the North American toadstool Lepiota americana, respectively. In particular, Aulinger et al. isolated red-colored APO and orange-colored lepiotaquinone, both of which are metabolites of o-aminophenol, from the red-colored acetone extract of fruit bodies of Lepiota Americana. The white flesh of Lepiota americana turns yelloworange on bruising, becoming red over time. 50) Furthermore, in our preliminary study we detected the presence of oaminophenol in the ethanol extract of the brown mushroom by HPLC analysis, while o-aminophenol was not detected in the extracts of other mushrooms that exhibited no inhibitory effects on NO production by LPS/IFN-g-stimulated peritoneal macrophages. These results suggest a possibility that APO is synthesized via o-aminophenol in some species of mushrooms including the brown mushroom, although the exact synthetic pathway leading to APO in the mushroom needs to be elucidated.
In summary, we have shown here that APO isolated from the extract of an edible brown mushroom inhibited the production of pro-inflammatory mediators NO and PGE 2 , and inflammatory cytokines IL-6 and IL-12 by LPS-and/or IFNg-activated macrophages. In addition, APO induced antigenstimulated Th cells to produce the anti-inflammatory cytokine IL-4. Our preliminary study showed that oral administration of 500 to 1500 mg/kg APO into ddY mice did not cause weight loss or gastrointestinal injury (data not shown). Furthermore, although APO was originally isolated as an antibacterial substance, no diarrhea was observed after repeated oral administration of 10 mg/kg APO into mice for 4 weeks (data not shown). Thus, our results suggested that APO could provide a promising therapeutic strategy in terms of safety and efficacy for T cell-mediated inflammatory autoimmune disease as well as for bacterially-induced disease.
